6,6-dimethyl-1-cyclohexenecarboxaldehyde | 115463-65-5

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机氧化物
• 英文名称: 6,6-dimethyl-1-cyclohexenecarboxaldehyde
• 英文别名: 6,6-dimethylcyclohex-1-enecarbaldehyde；6,6-dimethyl-cyclohex-1-enecarbaldehyde；6,6-Dimethyl-cyclohex-1-encarbaldehyd；6,6-Dimethylcyclohex-1-ene-1-carbaldehyde；6,6-dimethylcyclohexene-1-carbaldehyde
• CAS: 115463-65-5
• 化学式: C₉H₁₄O
• 分子量: 138.21
• InChiKey: WGKMOCKIIICBCR-UHFFFAOYSA-N

物化性质

• 沸点：
  195.6±19.0 °C(Predicted)
• 密度：
  0.968±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6,6-dimethyl-1-cyclohexenecarboxaldehyde 在 diisobutylammonium hydride 作用下， 以 正己烷 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 6,6-dimethyl-1-cyclohexenemethanol
  参考文献：
  名称：

  .beta.-Hydroxy esters: (E)- versus (Z)-enolate geometry in dianionic Claisen rearrangements

  摘要：

  DOI：

  10.1021/jo00252a037
• 作为产物：
  描述：

  2,2-二甲基环己酮 在 盐酸 、 正丁基锂 、 四甲基乙二胺 作用下， 反应 2.52h， 生成 6,6-dimethyl-1-cyclohexenecarboxaldehyde
  参考文献：
  名称：

  .beta.-Hydroxy esters: (E)- versus (Z)-enolate geometry in dianionic Claisen rearrangements

  摘要：

  DOI：

  10.1021/jo00252a037

文献信息

• [EN] OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] LIGANDS LIANT L'OPSINE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：BIKAM PHARMACEUTICALS INC

  公开号：WO2013081642A1

  公开（公告）日：2013-06-06

  Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

  揭示了用于治疗由于或与在眼睛中积聚的有毒视觉循环产物有关的眼科疾病的化合物和组合物，例如干性成人黄斑变性，以及由于或与突变视蛋白的错误折叠和/或视蛋白的错误定位有关的疾病。还描述了这些化合物单独或与其他治疗剂的组合物，以及使用这些化合物和/或组合物的治疗方法。还揭示了合成这些药剂的方法。
• 5-Demethylretinal and its 5-2H, 7-2H2 and 5,7-2H2 isotopomers. Synthesis, photochemistry and spectroscopy
  作者：M. B. Spijker-Assink、C. Winkel、G. S. Baldwin、J. Lugtenburg

  DOI：10.1002/recl.19881070304

  日期：——

  All-trans-5-demethylretinal and its 5-2H, 7-2H and 5,7-2H2 isotopomers have been synthesized by means of a new and simple scheme. Using photochemistry, the 9-, 11- and 13-cis, as well as the 9,13- and 11,13-di-cis isomers, were obtained. The structures were established by means of 1H NMR spectroscopy.

  清一色反式-5- demethylretinal和其5- 2 H，7- 2 H和5,7- 2 ħ 2同位素已经由新的和简单的方案来合成。使用光化学，获得9-，11-和13-顺式以及9,13-和11,13-顺式异构体。通过1 H NMR光谱确定结构。
• Total Synthesis of (+/−)-Frondosin B and (+/−)-5-<i>epi</i>-Liphagal by Using a Concise (4+3) Cycloaddition Approach
  作者：Duchan R. Laplace、Bart Verbraeken、Kristof Van Hecke、Johan M. Winne

  DOI：10.1002/chem.201303273

  日期：2014.1.3

  developed (4+3) cycloaddition between dienes and furfuryl alcohols, as precursors of oxyallyl‐type cations, has been used as a key step in the racemic syntheses of two natural products: frondosin B and liphagal. This work demonstrates the synthetic potential of this cycloaddition reaction, and offers a short synthetic route to an interesting family of natural products. A full account of these synthetic studies

  作为氧烯丙基型阳离子的前体，二烯和糠醇之间最近开发的（4 + 3）环加成反应已被用作frondosin B和脂质体这两种天然产物外消旋合成的关键步骤。这项工作证明了这种环加成反应的合成潜力，并提供了一条有趣的天然产物家族的短合成路线。完整介绍了这些合成研究，进一步说明了这种简单的七元环合成方法的机理，范围和局限性。
• Opsin-Binding Ligands, Compositions and Methods of Use
  申请人：Bikam Pharmaceuticals, Inc.

  公开号：US20150038574A1

  公开（公告）日：2015-02-05

  Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

  本文披露了一些化合物和组合物，用于治疗由于或与眼睛中毒性视觉循环产物积累有关的眼科疾病，如干性成人黄斑变性，以及由突变视蛋白的错误折叠和/或视蛋白的错误定位引起或有关的疾病。描述了这些化合物单独或与其他治疗剂组合的组合物，以及使用这些化合物和/或组合物的治疗方法。还披露了合成这些药剂的方法。
• Opsin-binding ligands, compositions and methods of use
  申请人：Bikam Pharmaceuticals, Inc.

  公开号：US10040749B2

  公开（公告）日：2018-08-07

  Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

  所公开的化合物和组合物可用于治疗因产生积聚在眼内的有毒视觉循环产物而引起或与之相关的眼科疾病，如干性成人黄斑变性，以及因突变视蛋白的错误折叠和/或视蛋白的错误定位而引起或与之相关的疾病。此外，还描述了这些化合物单独或与其他治疗剂结合的组合物，以及使用这些化合物和/或组合物的治疗方法。还公开了合成此类制剂的方法。